Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin

Summary

Primary objective: * End-point improvement from baseline in Male Sexual Health Questionnaire Ejaculation domain (MSHQ-EjD)in men with lower urinary tract symptoms (LUTS)suggestive of benign prostatic hyperplasia (BPH) treated for 6 months with XATRAL 10mg once daily OD. Secondary objectives: * MSHQ-EjD improvement by visit * Improvement in International Prostate Symptom Score (IPSS) total score, voiding and filling subscores, nocturia and bother score at end-point and by visit * Onset of action of XATRAL 10mg OD * Tolerability of XATRAL 10mg OD including occurrence of acute urinary retention.

Timeline

Start

2006-06

Primary completion

2007-12

Completion

—

Drugs

Indications